Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

igen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnership for Empatic on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news rele
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... August 31, 2014 The Global ... professional and in-depth study on the current state ... and China. , The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: ... in China, announced today that Dr. Weidong Yin, President and ... Helen Yang, Investor Relations Manager, are scheduled to attend four ... Rodman & Renshaw Annual Global Investment Conference, New ...
... ProteinSimple today introduced a revolutionary new system for protein analysis, ... complete reinvention of the Western Blot, and is truly a ... 30 years, researchers have access to a completely automated, walk-away ... was invented in 1979 and to this day remains the ...
... Technologies Corporation (NASDAQ: LIFE ) today announced ... Sciences Conference on Tuesday, September 20 at 8:00am ET. ... will present on behalf of the company. The company ... three weeks following the conference on the Life Technologies, ...
Cached Biology Technology:Sinovac to Participate in Four Investor Conferences in September 2011 2ProteinSimple Reinvents the Western Blot 2Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2
(Date:9/2/2014)... that digital distribution of media will have lower ... least when file sizes are large. , That,s ... Journal of Industrial Ecology that looked ... such as PlayStation3. Researchers found that Blu-ray Discs ... emissions than game files downloaded over broadband Internet. ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... September issue of The FASEB Journal , ... diagnose the leading cause of blindness in adults, ... This advance involves quantifying the early molecular changes ... vessels. Using new probes developed by scientists, they ... of diabetic retinopathy. , "My goal is to ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... a team led by researchers from Caltech has for ... of chemoreceptorsthe receptors that sense and respond to chemical ... specific architecture is the same throughout a wide variety ... stable, universal structure that has been conserved over evolutionary ...
... new university/industry network to pursue the development of biomaterials, ... increasing incidence of eye disease. The 20/20: NSERC ... as part of the Natural Sciences and Engineering Research ... Minister of State (Science and Technology) Gary Goodyear today ...
... cell researcher Treena Livingston Arinzeh will discuss current stem cell ... for bone fracture and osteoarthritis treatments, spinal cord repair, and ... The event will be held Sept. 29, 2009, at ... floor of the NJIT Campus Center. The ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4New research network at McMaster aims to build a better eye 2
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
...
EoProbe Eosinophil Staining Kit, 1 Kit...
... ELISA Development kit contains the basic components ... to measure natural and recombinant rat L-Selectin ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
Biology Products: